RATIO-GALANTAMINE DIN 02270803
Status: Cancelled Pre Market
Holder: RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
Molecule: GALANTAMINE (GALANTAMINE HYDROBROMIDE)
Health Canada record
| Active ingredient(s) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 12 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06DA04 GALANTAMINE |
| Original market date | |
| Current status date | 16-Oct-2015 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GALANTAMINE (GALANTAMINE HYDROBROMIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02293048 | APO-GALANTAMINE | APOTEX INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Approved |
| 02293056 | APO-GALANTAMINE | APOTEX INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 12 MG | Approved |
| 02293021 | APO-GALANTAMINE | APOTEX INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 4 MG | Approved |
| 02425165 | AURO-GALANTAMINE ER | AURO PHARMA INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Marketed |
| 02425173 | AURO-GALANTAMINE ER | AURO PHARMA INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Marketed |
| 02425157 | AURO-GALANTAMINE ER | AURO PHARMA INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Marketed |
| 02316951 | GALANTAMINE ER | ESSENTIAL PHARMA SWITZERLAND GMBH | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Marketed |
| 02316978 | GALANTAMINE ER | ESSENTIAL PHARMA SWITZERLAND GMBH | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Marketed |
| 02443023 | GALANTAMINE ER | SANIS HEALTH INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Marketed |
| 02443015 | GALANTAMINE ER | SANIS HEALTH INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Marketed |
| 02562170 | GALANTAMINE ER | SIVEM PHARMACEUTICALS ULC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Marketed |
| 02562162 | GALANTAMINE ER | SIVEM PHARMACEUTICALS ULC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Marketed |
| 02562154 | GALANTAMINE ER | SIVEM PHARMACEUTICALS ULC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Marketed |
| 02443031 | GALANTAMINE ER | SANIS HEALTH INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Marketed |
| 02316943 | GALANTAMINE ER | ESSENTIAL PHARMA SWITZERLAND GMBH | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Marketed |
| 02419238 | IPG-GALANTAMINE ER | MARCAN PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Approved |
| 02419254 | IPG-GALANTAMINE ER | MARCAN PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Approved |
| 02419246 | IPG-GALANTAMINE ER | MARCAN PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Approved |
| 02570947 | MINT-GALANTAMINE ER | MINT PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Approved |
| 02570939 | MINT-GALANTAMINE ER | MINT PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Approved |
| 02570955 | MINT-GALANTAMINE ER | MINT PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Approved |
| 02339439 | MYLAN-GALANTAMINE ER | MYLAN PHARMACEUTICALS ULC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Marketed |
| 02339455 | MYLAN-GALANTAMINE ER | MYLAN PHARMACEUTICALS ULC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Marketed |
| 02339447 | MYLAN-GALANTAMINE ER | MYLAN PHARMACEUTICALS ULC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Marketed |
| 02427273 | PENDO-GALANTAMINE ER | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Approved |
| 02333392 | PMS-GALANTAMINE | PHARMASCIENCE INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 12 MG | Approved |
| 02333376 | PMS-GALANTAMINE | PHARMASCIENCE INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 4 MG | Approved |
| 02333384 | PMS-GALANTAMINE | PHARMASCIENCE INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Approved |
| 02416603 | GALANTAMINE ER | PRO DOC LIMITEE | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Cancelled Post Market |
| 02416573 | GALANTAMINE ER | PRO DOC LIMITEE | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Post Market |
| 02416581 | GALANTAMINE ER | PRO DOC LIMITEE | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Cancelled Post Market |
| 02420856 | MAR-GALANTAMINE ER | MARCAN PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Cancelled Post Market |
| 02420821 | MAR-GALANTAMINE ER | MARCAN PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Post Market |
| 02420848 | MAR-GALANTAMINE ER | MARCAN PHARMACEUTICALS INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Cancelled Post Market |
| 02398397 | PMS-GALANTAMINE ER | PHARMASCIENCE INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Cancelled Post Market |
| 02398389 | PMS-GALANTAMINE ER | PHARMASCIENCE INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Cancelled Post Market |
| 02398370 | PMS-GALANTAMINE ER | PHARMASCIENCE INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Post Market |
| 02270773 | RATIO-GALANTAMINE | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 4 MG | Cancelled Pre Market |
| 02270781 | RATIO-GALANTAMINE | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Pre Market |
| 02244300 | REMINYL -(12MG) | JANSSEN INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 12 MG | Cancelled Post Market |
| 02244298 | REMINYL -(4MG) | JANSSEN INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 4 MG | Cancelled Post Market |
| 02244299 | REMINYL -(8MG) | JANSSEN INC | Tablet | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Post Market |
| 02266717 | REMINYL ER | JANSSEN INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Post Market |
| 02266733 | REMINYL ER | JANSSEN INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Cancelled Post Market |
| 02266725 | REMINYL ER | JANSSEN INC | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Cancelled Post Market |
| 02392305 | SANDOZ GALANTAMINE ER | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Cancelled Pre Market |
| 02392283 | SANDOZ GALANTAMINE ER | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Pre Market |
| 02392291 | SANDOZ GALANTAMINE ER | SANDOZ CANADA INCORPORATED | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Cancelled Pre Market |
| 02377950 | TEVA-GALANTAMINE ER | TEVA CANADA LIMITED | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8 MG | Cancelled Post Market |
| 02377969 | TEVA-GALANTAMINE ER | TEVA CANADA LIMITED | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16 MG | Cancelled Post Market |
| 02377977 | TEVA-GALANTAMINE ER | TEVA CANADA LIMITED | Capsule (Extended-Release) | GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 10838 | 2009-12-08 | Abbreviated New Drug Submission (ANDS) |